Loading...
Environmental nontuberculous mycobacteria such as Mycobacterium kansasii can cause opportunistic pulmonary infections requiring multiple antibiotic regimens for at least 1 year. The recent availability of new antibiotics such as omadacycline (a tetracycline approved for soft-tissue infection and community-acquired bacterial pneumonia) opens opportunities to explore alternative therapies offering shorter-course options.
Singh and colleagues evaluated the activity in vitro of omadacycline against a reference strain of M. kansasii as well as 21 clinical isolates and found minimum inhibitory concentrations (MICs) of 4 to 32 mg/L. A hollow fiber system model was used to evaluate several human-equivalent omadacycline doses. The optimal exposure fo…